Fresenius pulls out of $4.3bn Akorn merger
German healthcare firm Fresenius Kabi is walking away from a $4.3-billion merger with US generics group Akorn, claiming that the latter has failed to fulfill several closing conditions.
Read More
Tag: Fresenius
Merck sells biosimilars business to Fresenius
Merck has divested its biosimilars business to fellow German drugmaker Fresenius in a deal potentially worth 670 million euros.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
